PharVision Advisers’s Globus Medical GMED Stock Holding History

PharVision Advisers’s Portfolio GMED Stock Details GMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,101	Closed	-$339K	–	367
2024 Q4	$339K	Buy	+4,101	New	+$323K	0.29%	117

Other funds holding GMED

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BAM

Burgundy Asset Management Toronto, Ontario, Canada $10.6B AUM 13.39% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PharVision Advisers's GMED Position: Q1 2025 in Review

PharVision Advisers sold out of Globus Medical (GMED) in Q1 2025, closing a stake of 4,101 shares — an estimated $339K sold.

PharVision Advisers first reported a position in GMED in Q4 2024 and held it in 1 quarter. The position peaked at $339K in Q4 2024. 514 funds tracked by Wall St. Rank hold GMED as of Q1 2025.

PharVision Advisers reported no remaining Globus Medical position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 4,101 Globus Medical shares in Q1 2025, an estimated $339K.
PharVision Advisers first reported a position in Globus Medical in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Globus Medical position peaked at $339K in Q4 2024.
514 funds tracked by Wall St. Rank held Globus Medical as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.